



Multimodality and Sequential Therapy in Locally Advanced Head and Neck Cancer

Guest Editors:

Prof. Dr. Giancarlo Pecorari

Division of Otorhinolaryngology,
Department of Surgical Sciences,
University of Turin, 10126 Torino,
Italy

Dr. Giuseppe Riva

Department of Surgical Sciences,
University of Turin, 10126 Torino,
Italy

Deadline for manuscript
submissions:

closed (30 April 2022)

Message from the Guest Editors

Dear Colleagues,

The treatment of locally advanced head and neck cancer is often challenging. Despite the surgical and nonsurgical innovations in the last few decades, the oncologic and functional outcomes are not always improved. Multimodality and sequential therapy arose for locally advanced cancers and included induction chemotherapy, chemoradiation with organ-preservation protocols, immunotherapy, and targeted therapy. Surgery remains an important option, including after chemoradiotherapy failure. Moreover, treatment-related toxicity negatively affects patients' quality of life and should be taken into account during treatment choice.

This Special Issue aims to highlight the current state of the art and to describe future perspectives for the multimodal management of locally advanced head and neck cancer. In particular, original research articles and reviews on sequential treatment, but also on the role of surgery after induction chemotherapy or as a salvage approach, are welcome.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)